Get the Stockscreener App
10.46
3.86%
-0.42
After Hours:
10.44
-0.02
-0.19%
Emergent Biosolutions Inc Stock (EBS) Latest News
Emergent BioSolutions (NYSE:EBS) Trading Down 7%Here's Why - MarketBeat
Emergent BioSolutions (NYSE:EBS) Shares Down 3.9%What's Next? - MarketBeat
Where are the Opportunities in (EBS) - Stock Traders Daily
Emergent BioSolutions up 10% on HC Wainwright buy initiation - MSN
Emergent BioSolutions’ CEO Sold $11 Million worth of stock before error in Baltimore went public - WBAL Radio
Emergent BioSolutions Inc. to Host Earnings Call - ACCESS Newswire
Emergent BioSolutions (NYSE:EBS) Stock Rating Lowered by StockNews.com - MarketBeat
Emergent BioSolutions Inc (EBS) Stock Price Up 3.4% on Jan 24 - GuruFocus.com
Emergent BioSolutions (NYSE:EBS) Trading 7.2% HigherTime to Buy? - MarketBeat
Emergent seeking to reverse fortunes and become a major overdose treatment player - Pharmaceutical Technology
There's No Escaping Emergent BioSolutions Inc.'s (NYSE:EBS) Muted Revenues Despite A 26% Share Price Rise - Simply Wall St
Emergent BioSolutions stock reaffirms buy rating on contract modification - MSN
Emergent BioSolutions (NYSE:EBS) Earns "Buy" Rating from HC Wainwright - MarketBeat
Emergent BioSolutions stock reaffirms buy rating on contract modification By Investing.com - Investing.com UK
The Analyst Verdict: Emergent BioSolutions In The Eyes Of 4 Experts - Benzinga
EBS (Emergent BioSolutions) Revenue : $1,094 Mil (TTM As of Sep. 2024) - GuruFocus.com
Blood Plasma Market Growing at 4.07% CAGR to Hit 42.0 Billion USD by 2032 | Emergent BioSolutions, ADMA - EIN News
Barclays PLC Has $329,000 Stake in Emergent BioSolutions Inc. (NYSE:EBS) - MarketBeat
EBS (Emergent BioSolutions) Free Cash Flow : $138 Mil (TTM As of Sep. 2024) - GuruFocus.com
Emergent BioSolutions gains exclusive commercial rights to KLOXXADO - MSN
Africa CDC Launches Groundbreaking Pan-African Mpox Treatment Trial in DRC - StockTitan
Emergent BioSolutions presents at healthcare conference By Investing.com - Investing.com Australia
Emergent BioSolutions Outlines Growth at J.P. Morgan Conference - TipRanks
Emergent BioSolutions presents at healthcare conference - Investing.com
Rep. Steve Cohen Sells Emergent BioSolutions Inc. (NYSE:EBS) Stock - MarketBeat
StockNews.com Upgrades Emergent BioSolutions (NYSE:EBS) to Buy - MarketBeat
Emergent secures rights to KLOXXADO nasal spray By Investing.com - Investing.com Canada
Hikma announces exclusive commercial partnership with Emergent BioSolutions for KLOXXADO® (naloxone HCl) nasal spray 8 mg - The Malaysian Reserve
Hikma announces exclusive commercial partnership with Emergent B - GuruFocus.com
Emergent secures rights to KLOXXADO nasal spray - Investing.com
Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals - The Manila Times
Emergent BioSolutions: Stock Is A Likely Winner In 2025 (NYSE:EBS) - Seeking Alpha
Hikma Partners with Emergent BioSolutions for KLOXXADO® Opioid Overdose Treatment Distribution - StockTitan
Emergent BioSolutions Expands Overdose Treatment Portfolio with Exclusive KLOXXADO Rights - StockTitan
Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola - The Manila Times
Emergent BioSolutions Secures $16.7M BARDA Contract for Ebola Treatment Development - StockTitan
Emergent BioSolutions exercises $20M option to supply DoD with BioThrax - MSN
HC Wainwright Reiterates Buy Rating for Emergent BioSolutions (NYSE:EBS) - MarketBeat
Those who invested in Emergent BioSolutions (NYSE:EBS) a year ago are up 365% - Yahoo Finance
Emergent BioSolutions Receives $20 Million Contract to Supply Anthrax Vaccine to US Military - Marketscreener.com
Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed) - The Manila Times
Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 - Marketscreener.com
Emergent BioSolutions Secures $20M Defense Contract for Anthrax Vaccine BioThrax - StockTitan
Emergent Stock Skyrockets 251% YTD: How to Play the Stock? - MSN
The 13% return this week takes Emergent BioSolutions' (NYSE:EBS) shareholders one-year gains to 285% - Simply Wall St
HC Wainwright & Co. Initiates Coverage of Emergent BioSolutions (EBS) with Buy Recommendation - MSN
0.25%
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):